Home MOREBUSINESS & ECONOMY EU Commission signs Joint Procurement contract with HIPRA for COVID-19 vaccines

EU Commission signs Joint Procurement contract with HIPRA for COVID-19 vaccines

by asma
0 comment

HERA, the European Commission’s Health Preparedness and Response Authority, has signed a joint procurement Framework Contract with the company HIPRA HUMAN HEALTH for the supply of their protein COVID-19 vaccine. 14 Member States and countries are participating in this joint procurement, under which they can purchase up to 250 million doses. As the number of cases is again on the rise in Europe, this agreement will make the HIPRA vaccine rapidly available to the participating countries, as soon as this vaccine has received a positive assessment by the European Medicines Agency.

Commissioner for Health and Food Safety, Stella Kyriakides, said: “With COVID-19 infections on the rise in Europe, we need to ensure maximum preparedness as we head into the autumn and winter months. The HIPRA vaccine adds yet another option to complement our broad vaccine portfolio for our Member States and citizens. An increase in vaccination and boosting is essential over the coming months. We are working tirelessly to make sure there are vaccines available for all. This is our European Health Union in action – preparing ahead and being ready to act.”

The joint procurement contract with HIPRA complements an already broad portfolio of vaccines secured through the EU Vaccines Strategy, including the contracts already signed with AstraZenecaSanofi-GSKJanssen Pharmaceutica NVBioNtech-Pfizer, ModernaNovavaxand Valneva. Some 4.2 billion doses have been secured under the EU Vaccines Strategy. This diversified vaccine portfolio will ensure Europe continues to be well prepared for COVID-19 vaccination, using vaccines that have been proven to be safe and effective. Participating countries could decide to donate the vaccines to lower and middle-income countries or to re-direct them to other European countries.

The HIPRA bivalent recombinant protein vaccine, which is currently under rolling review by the European Medicines Agency, is being developed as a booster dose in previously immunized persons 16 years and older. The HIPRA vaccine is stored at refrigerated temperature between 2 and 8ºC, facilitating storage and distribution in Europe and across the world.

Follow EU Today on Social media:

You may also like

Leave a Comment

EU Today brings you the latest news and commentary from across the EU and beyond.

Editors' Picks

Latest Posts